Dear Editor,

Thank you for the contributions. In the letter, 3 important topics about our study were pointed out: location of residual stone fragments, initial access location, and absence of medium term stone-free rate (SFR) [1]. Hence, it is important for us to briefly clarify these issues. Surgeons who frequently performed percutaneous nephrolithotomy (PCNL) may have experienced the difficulty of reaching anterior calyx stones. However, there are not enough studies on this subject in the literature [2-4]. We aimed to be a preliminary work in this matter with this study.

As the authors have stated the specific localization of the residual stone is very important, but unfortunately it can only be detected by postoperative computed tomography (CT) in all patients. Because of the retrospective nature of our study, not all patients performed CT.

Another subject mentioned by the authors was the initial access localization. The second paragraph of the letter emphasized the difficulty of reaching to the anterior calyx. However, this conclusion requires citation. Our goal with this study was try to fill this gap in the literature. The initial access localization was not evaluated because it was outside the purpose of our study. Moreover, the authors stated in the fourth paragraph that “but in this study, the initial access localization was not reported. The localization of the initial access is one of the most important parameters affecting the stone-free rate, especially in complex stones. For example, upper pole access is an effective way to achieve higher SFRs, especially in staghorn or complex kidney stones.” Nevertheless, to our knowledge, there is no consensus about where initial puncture should be in the treatment of complex stones with PCNL. Many studies have shown that upper pole access is an independent risk factor that increases complication rates in PCNL and recommended when multiple access is required, not recommended for initial access [5-12].

The last point that the authors draw attention was the absence of medium term SFR in our study which was one of the most important limitations of our study. We could not access sufficient data because of retrospective nature of our study.

We consider the effect of anterior calyx stones in the management of nephrolithiasis as a subject worth researching. We believe that the missing points mentioned in this article should be revealed through prospective well-designed studies. We owe thanks to the authors for their valuable contribution.

The authors have no conflicts of interest to declare.

The authors did not receive any funding.

A.K.: writing/editing, and data collection or management; N.C.C., A.O., O.F., M.A., and C.T.G.: performed data collection or management; and Z.T.: critical revision.

1.
Şahan
A
,
Çubuk
A
,
Özkaptan
O
.
Letter to the editor regarding the article “impact of anterior kidney calyx involvement of complex stones on outcomes for patients undergoing percutaneous nephrolithotomy”
.
Urol Int
.
2020
;
1
2
.
2.
Tepeler
A
,
Bozkurt
OF
,
Resorlu
B
,
Silay
MS
,
Ozyuvali
E
,
Ersoz
C
, et al.
Is the percutaneous nephrolithotomy procedure complicated in patients with anterior caliceal stones?
Urol Int
.
2013
;
90
(
4
):
389
93
.
3.
El-Shazly
M
,
Aziz
M
,
Omar
M
,
Al-Hunaidi
O
,
El-Nahas
AR
.
Management of anterior caliceal stones >15 mm
.
Urolithiasis
.
2016
;
44
(
4
):
377
81
.
4.
Kalkanli
A
,
Cilesiz
NC
,
Fikri
O
,
Ozkan
,
A
,
Gezmis
CT
,
Aydin
M
, et al.
Impact of anterior kidney calyx involvement of complex stones on outcomes for patients undergoing percutaneous nephrolithotomy
.
Urol Int
.
2020
;
104
(
5–6
):
459
64
.
5.
Tefekli
A
,
Esen
T
,
Olbert
PJ
,
Tolley
D
,
Nadler
RB
,
Sun
YH
, et al.
Isolated upper pole access in percutaneous nephrolithotomy: a large-scale analysis from the CROES percutaneous nephrolithotomy global study
.
J Urol
.
2013
;
189
(
2
):
568
73
.
6.
Soares
RMO
,
Zhu
A
,
Talati
VM
,
Nadler
RB
.
Upper pole access for prone percutaneous nephrolithotomy: advantage or risk?
Urology
.
2019
;
134
:
66
71
.
7.
El-Karamany
T
.
A supracostal approach for percutaneous nephrolithotomy of staghorn calculi: a prospective study and review of previous reports
.
Arab J Urol
.
2012
;
10
(
4
):
358
66
.
8.
Olvera-Posada
D
,
Tailly
T
,
Alenezi
H
,
Violette
PD
,
Nott
L
,
Denstedt
JD
, et al.
Risk factors for postoperative complications of percutaneous nephrolithotomy at a tertiary referral center
.
J Urol
.
2015
;
194
(
6
):
1646
51
.
9.
Munver
R
,
Delvecchio
FC
,
Newman
GE
,
Preminger
GM
.
Critical analysis of supracostal access for percutaneous renal surgery
.
J Urol
.
2001
;
166
(
4
):
1242
6
.
10.
Netto
NR
 Jr
,
Ikonomidis
J
,
Ikari
O
,
Claro
JA
.
Comparative study of percutaneous access for staghorn calculi
.
Urology
.
2005
;
65
(
4
):
659
63
.
11.
Klein
I
,
Gutiérrez-Aceves
J
.
Preoperative imaging in staghorn calculi, planning and decision making in management of staghorn calculi
.
Asian J Urol
.
2020
;
7
(
2
):
87
93
.
12.
Vande Lune
PL
,
Thayer
D
,
Mani
N
,
Warren
A
,
Desai
AC
,
Picus
DJ
, et al.
Image-guided access for percutaneous nephrolithotomy: a single-center experience in 591 patients
.
Curr Urol
.
2019
;
12
(
4
):
210
5
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.